Lupus-Nephritis

Pathogenesis-Directed Lupus Therapeutics

A 2026 review of pathogenesis-directed SLE therapeutics anchored to the 2025 ACR SLE and 2024 ACR lupus nephritis guidelines — the FDA-approved and off-label drugs by mechanism, indication and monitoring, plus the metabolic/mitochondrial, IL-1, cardiometabolic and non-pharmacological strategies, mapped by organ manifestation.

June 21, 2026 · 8 min
Independent educational summaries for healthcare professionals. Not medical advice. Each post is an original summary of the cited source; copyright in the original works remains with their authors and publishers. See the About & Disclaimer page.